Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|May 2, 2010
- Pharmaceutical Technology-05-02-2010
- Volume 34
- Issue 5
Q&A with Schenk AccuRate's Chad Lorensen
Lorensen discusses client demands and industry trends.
Advertisement
Q & A with
Chad Lorensen, pharmaceutical industry business-development manager of Schenck AccuRate
PharmTech:
What is the biggest industry challenge you're now facing?
Lorensen
The development of continuous manufacturing processes. We are monitoring, helping where we can, and working with companies in the pharmaceutical industry who are studying continuous manufacturing processes for solid dosage products. Our core products have the strengths that provide value for this type of manufacturing process.
PharmTech:
How do you stay abreast of new developments in the industry?
Lorensen
Schenck stays abreast of the latest industry developments through regular communication with our customers, developing strong working relationships with other pharmaceutical-industry equipment manufacturers, and by participating in research consortiums at various universities. Further information is gathered by reviewing various pharmaceutical periodicals and attending trade show exhibitions. In addition, Schenck is a global company, and each of its offices can share ideas with other Schenck locations throughout the world.
PharmTech:
Do you see a new industry trend emerging?
Lorensen
We are looking forward to the pharmaceutical industry's acceptance of continuous mixing, granulation, and hot-melt extrusion.
PharmTech:
What is the most common demand your clients are currently making of you?
Lorensen
The most common request is to provide equipment to customers' sites for trials and experiments made in conjunction with other types of continuous processing equipment.
Articles in this issue
over 16 years ago
Pharmaceutical Technology, May 2010 Issue (PDF)over 16 years ago
Inside USP: The USP Conventionover 16 years ago
Health Reform to Transform Coverage, Costsover 16 years ago
Statistical Solutions: Bergum's Method Recognizedover 16 years ago
A Very Brady FDAover 16 years ago
Experimental Considerations in Headspace Gas Chromatographyover 16 years ago
The Lilly Wayover 16 years ago
Exploring Catalysis in API Synthesisover 16 years ago
Skin Permeation of Rosiglitazone from Transdermal Matrix Patchesover 16 years ago
Report from Brazil May 2010Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement